Neoprogen is now Secretome Therapeutics, in alignment with the company’s focus in revolutionizing cell therapy via neonatal cardiac progenitor cells (nCPCs) and their respective secretomes 

by secretome | Jun 1, 2023 | Investors, News, Uncategorized

NeoProgen receives approval from U.S. FDA for a Phase I Study of The Safety And Early Efficacy of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) In Chronic Ischemic Heart Failure

by secretome | May 23, 2023 | Investors, News

BALTIMORE, MD., June 10, 2021 — NeoProgen, Inc., a pre-clinical stage company developing an exosome-based product from human neonatal heart-derived Medicinal Signaling Cells (nMSCs) for tissue repair and regeneration for the treatment of heart failure (HF) and other...

NeoProgen, Inc. Receives First Granted Patent for Method to Treat Cardiac Conditions using Neonatal Heart-derived Medicinal Signaling Cells (nMSCs) and/or their Secretomes/Exosomes from the US Patent Office

by secretome | May 23, 2023 | Investors, News

BALTIMORE–(BUSINESS WIRE)–NeoProgen, Inc., a pre-clinical stage company developing an exosome-based product from human neonatal heart-derived Medicinal Signaling Cells (nMSCs) for tissue repair and regeneration for the treatment of heart failure (HF) and...

Secretome Therapeutics Presents Scientific Poster on the Essential Role of Complete Secretome in Regenerative Cell Therapy at ISSCR 2023 Annual Meeting

by secretome | May 16, 2023 | Investors, News

[DALLAS, TX – May 12, 2023] — Secretome Therapeutics, a pioneering biotechnology company focused on developing regenerative cell therapies, is pleased to announce its participation in the prestigious ISSCR 2023 Annual Meeting, held at the Boston Convention and...

Secretome Therapeutics Announces Appointment of Angela Shen, M.D., M.B.A., to Board of Directors

by secretome | Oct 4, 2022 | News, Uncategorized

Secretome Therapeutics, a preclinical company developing novel therapies derived from neonatal mesenchymal stem cells, today announced the appointment of Angela Shen, M.D., M.B.A, to its Board of Directors. Dr. Shen is currently the Vice President, Strategic...

Maryland Stem Cell Research Commission Announces $1,351,400 Million in Stem Cell Program Awards

by secretome | Sep 10, 2019 | News, Uncategorized

The Maryland Stem Cell Research Commission (Commission) has approved funding to its first round of fiscal year 2020 recipients for a total of $1,351,400. The Commission has also announced new leadership with the election of a new chair and vice chair to serve for the...